These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24995344)

  • 21. A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.
    Sha J; Kirtley ML; Klages C; Erova TE; Telepnev M; Ponnusamy D; Fitts EC; Baze WB; Sivasubramani SK; Lawrence WS; Patrikeev I; Peel JE; Andersson JA; Kozlova EV; Tiner BL; Peterson JW; McWilliams D; Patel S; Rothe E; Motin VL; Chopra AK
    Clin Vaccine Immunol; 2016 Jul; 23(7):586-600. PubMed ID: 27170642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel CTL epitopes identified through a Y. pestis proteome-wide analysis in the search for vaccine candidates against plague.
    Zvi A; Rotem S; Zauberman A; Elia U; Aftalion M; Bar-Haim E; Mamroud E; Cohen O
    Vaccine; 2017 Oct; 35(44):5995-6006. PubMed ID: 28606812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intramuscular Immunization of Mice with a Live-Attenuated Triple Mutant of Yersinia pestis CO92 Induces Robust Humoral and Cell-Mediated Immunity To Completely Protect Animals against Pneumonic Plague.
    Tiner BL; Sha J; Ponnusamy D; Baze WB; Fitts EC; Popov VL; van Lier CJ; Erova TE; Chopra AK
    Clin Vaccine Immunol; 2015 Dec; 22(12):1255-68. PubMed ID: 26446423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague.
    Levy Y; Flashner Y; Tidhar A; Zauberman A; Aftalion M; Lazar S; Gur D; Shafferman A; Mamroud E
    Vaccine; 2011 Sep; 29(40):6866-73. PubMed ID: 21803090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice.
    Brewoo JN; Powell TD; Stinchcomb DT; Osorio JE
    Vaccine; 2010 Aug; 28(36):5891-9. PubMed ID: 20638759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-dose intranasal subunit vaccine rapidly clears secondary sepsis in a high-dose pneumonic plague infection.
    D'Arco C; McCormick AA; Arnaboldi PM
    Vaccine; 2021 Mar; 39(9):1435-1444. PubMed ID: 33531196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modification of the Pulmonary MyD88 Inflammatory Response Underlies the Role of the Yersinia pestis Pigmentation Locus in Primary Pneumonic Plague.
    Olson RM; Dhariwala MO; Mitchell WJ; Skyberg JA; Anderson DM
    Infect Immun; 2021 Feb; 89(3):. PubMed ID: 33257532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague.
    Tao P; Mahalingam M; Zhu J; Moayeri M; Sha J; Lawrence WS; Leppla SH; Chopra AK; Rao VB
    mBio; 2018 Oct; 9(5):. PubMed ID: 30327445
    [No Abstract]   [Full Text] [Related]  

  • 29. Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague.
    Kumar D; Kirimanjeswara G; Metzger DW
    Clin Vaccine Immunol; 2011 Nov; 18(11):1925-35. PubMed ID: 21880856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague.
    Williamson ED; Stagg AJ; Eley SM; Taylor R; Green M; Jones SM; Titball RW
    Vaccine; 2007 Jan; 25(6):1142-8. PubMed ID: 17101198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A live attenuated strain of Yersinia pestis KIM as a vaccine against plague.
    Sun W; Six D; Kuang X; Roland KL; Raetz CR; Curtiss R
    Vaccine; 2011 Apr; 29(16):2986-98. PubMed ID: 21320544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity.
    Eyles JE; Butcher WA; Titball RW; Hill J
    Vaccine; 2007 Oct; 25(42):7301-6. PubMed ID: 17869388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell-mediated protection against pulmonary Yersinia pestis infection.
    Parent MA; Berggren KN; Kummer LW; Wilhelm LB; Szaba FM; Mullarky IK; Smiley ST
    Infect Immun; 2005 Nov; 73(11):7304-10. PubMed ID: 16239527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts.
    Arlen PA; Singleton M; Adamovicz JJ; Ding Y; Davoodi-Semiromi A; Daniell H
    Infect Immun; 2008 Aug; 76(8):3640-50. PubMed ID: 18505806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine.
    Huang J; D'Souza AJ; Alarcon JB; Mikszta JA; Ford BM; Ferriter MS; Evans M; Stewart T; Amemiya K; Ulrich RG; Sullivan VJ
    Clin Vaccine Immunol; 2009 May; 16(5):719-25. PubMed ID: 19261773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combinational deletion of three membrane protein-encoding genes highly attenuates yersinia pestis while retaining immunogenicity in a mouse model of pneumonic plague.
    Tiner BL; Sha J; Kirtley ML; Erova TE; Popov VL; Baze WB; van Lier CJ; Ponnusamy D; Andersson JA; Motin VL; Chauhan S; Chopra AK
    Infect Immun; 2015 Apr; 83(4):1318-38. PubMed ID: 25605764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antigen engineering can play a critical role in the protective immunity elicited by Yersinia pestis DNA vaccines.
    Wang S; Mboudjeka I; Goguen JD; Lu S
    Vaccine; 2010 Feb; 28(8):2011-9. PubMed ID: 20188257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response.
    Montminy SW; Khan N; McGrath S; Walkowicz MJ; Sharp F; Conlon JE; Fukase K; Kusumoto S; Sweet C; Miyake K; Akira S; Cotter RJ; Goguen JD; Lien E
    Nat Immunol; 2006 Oct; 7(10):1066-73. PubMed ID: 16980981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Yersinia pestis YscN ATPase mutant functions as a live attenuated vaccine against bubonic plague in mice.
    Bozue J; Cote CK; Webster W; Bassett A; Tobery S; Little S; Swietnicki W
    FEMS Microbiol Lett; 2012 Jul; 332(2):113-21. PubMed ID: 22537022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acquisition of maternal antibodies both from the placenta and by lactation protects mouse offspring from Yersinia pestis challenge.
    Qi Z; Zhao H; Zhang Q; Bi Y; Ren L; Zhang X; Yang H; Yang X; Wang Q; Li C; Zhou J; Xin Y; Yang Y; Yang H; Du Z; Tan Y; Han Y; Song Y; Zhou L; Zhang P; Cui Y; Yan Y; Zhou D; Yang R; Wang X
    Clin Vaccine Immunol; 2012 Nov; 19(11):1746-50. PubMed ID: 22933398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.